Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach

Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach

Medulloblastoma (MB) recurrence is usually incurable despite intensive therapy including high-dose chemotherapy. An evolving alternative approach to conventional chemotherapy aims at interfering with tumor angiogenesis at different levels. We report on a novel combinatorial metronomic antiangiogenic...

Full description

Bibliographic Details
Main Authors: Irene Slavc, Lisa Mayr, Natalia Stepien, Johannes Gojo, Maria Aliotti Lippolis, Amedeo A. Azizi, Monika Chocholous, Alicia Baumgartner, Cora S. Hedrich, Stefan Holm, Astrid Sehested, Pierre Leblond, Karin Dieckmann, Christine Haberler, Thomas Czech, Marcel Kool, Andreas Peyrl
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
medulloblastoma recurrence
antiangiogenic therapy
metronomic therapy
low-dose oral therapy
bevacizumab
intraventricular therapy
Online Access:https://www.mdpi.com/2072-6694/14/20/5128

Similar Items

Similar Items